Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Fellowship - PA: Eileen Iwanicki Fellowships in Breast Cancer Research

McGill University

$67,500.00

The Role of Rab-Coupling Protein in ErbB2-driven Mammary Tumourigenesis and Metastasis

EF 2012-13

Résumé
Genetic changes in breast cancer cells, including gene amplifications, deletions and mutations, alter the activity of cellular signaling pathways. This altered cell signaling is a crucial property underlying many aspects of tumour cell behavior. An important goal of the study of tumor cell signaling is to design drugs that block the activity of abnormal signaling pathways in tumour cells. This should be a highly efficacious strategy that avoids damaging normal cells and hence eliminates many of the harsh side effects of chemotherapy. Several such targeted therapies are in clinical use and many more are under development. Approximately 20-30% of breast cancers have amplification of the gene encoding a cell signaling receptor known as ErbB23HER2 (human epidermal growth factor receptor 2). These tumours express high levels of ErbB2, correlating with a poor prognosis for these patients. Targeted therapies directed against ErbB2 such as trastuzumab, an antibody, and lapatinib, an inhibitor of the enzyme activity of ErbB2, can extend the lifespan of ErbB2-positive breast cancer patients. However, many ErbB2-positive patients do not respond to these therapies, and resistance inevitably occurs in those patients who do responds. Recently, amplification and elevated expression of RCP (Rab-Coupling Protein) has been noted in 10-25% of primary breast cancer demonstrating intermediate level of ErbB2 and was further correlated with poor clinical outcome. The RCP is a novel gene candidate in the design of new therapy anti-ErbB2-positive cancer and ultimately improving the lifespan of suffering patient.
Programme
Fellowship - PA: Eileen Iwanicki Fellowships in Breast Cancer Research
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
270515
Name
Boulay Pierre-Luc
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Breast Cancer Society of Canada (North Sarnia, ON)
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
The Role of Rab-Coupling Protein in ErbB2-driven Mammary Tumourigenesis and Metastasis
Programtype2
Fellowship Programs
Orgnameinp2
McGill University
Cihramount2
$67,500
Cihrequipment2
$0
Programname2
Fellowship - PA: Eileen Iwanicki Fellowships in Breast Cancer Research
Keyworddelim
Breast Cancer; Mammary Gland; Mass Spectrometry; Metastasis; Oncogene; Primary Culture; Rna Interference; Signalling Pathway; Transgenic Mice; Tyrosine Kinase Receptor
Abstract
Genetic changes in breast cancer cells, including gene amplifications, deletions and mutations, alter the activity of cellular signaling pathways. This altered cell signaling is a crucial property underlying many aspects of tumour cell behavior. An important goal of the study of tumor cell signaling is to design drugs that block the activity of abnormal signaling pathways in tumour cells. This should be a highly efficacious strategy that avoids damaging normal cells and hence eliminates many of the harsh side effects of chemotherapy. Several such targeted therapies are in clinical use and many more are under development. Approximately 20-30% of breast cancers have amplification of the gene encoding a cell signaling receptor known as ErbB23HER2 (human epidermal growth factor receptor 2). These tumours express high levels of ErbB2, correlating with a poor prognosis for these patients. Targeted therapies directed against ErbB2 such as trastuzumab, an antibody, and lapatinib, an inhibitor of the enzyme activity of ErbB2, can extend the lifespan of ErbB2-positive breast cancer patients. However, many ErbB2-positive patients do not respond to these therapies, and resistance inevitably occurs in those patients who do responds. Recently, amplification and elevated expression of RCP (Rab-Coupling Protein) has been noted in 10-25% of primary breast cancer demonstrating intermediate level of ErbB2 and was further correlated with poor clinical outcome. The RCP is a novel gene candidate in the design of new therapy anti-ErbB2-positive cancer and ultimately improving the lifespan of suffering patient.
Competitiondate
201210
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Boulay, Pierre-Luc
Approvedterm
3 ans 0 mois
Cihrcontribution2
Breast Cancer Initiative~ $67,500~ $0~